A Phase 1 interventional study of ONO-7913 in Solid Tumor, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
Ono Pharmaceutical Co. Ltd is the lead sponsor of 66 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: ONO-7913
ONO-7913 will be administered by intravenous continuous infusion during the designated time.
Dose-limiting toxicities
Number of participants with a DLT
Time frame: 28 days
Adverse events
Assessed by the NCI CTCAE v5.0 criteria
Time frame: Up to 24 months
Concentration vs time of ONO-7913 as single dose
PK profile
Time frame: Up to 24 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ono Pharmaceutical Co. Ltd